|
Archived Press Releases
....................................................................................................................................................................................
These press releases about Oculus Incorporated are
sorted by date, with the most recent at the top. You will need the free Adobe®
Reader® to view the PDFs.
2008
June 23, 2008
Oculus
Innovative Sciences Announces Agreement With Bayer (Sichuan) Animal
Health Co. Ltd. for Development of Microcyn® Technology Use in
Chinese Animal Market
June 19, 2008
Oculus
Innovative Sciences Announces Agreement with Bayer Australia Limited
for Development of Microcyn® Technology Use in Australian Animal
Market
June 17, 2008
Oculus
Innovative Sciences Announces Development of Microcyn®-Based
Hydrogel Formulation
June 16, 2008
Oculus
Innovative Sciences Announces Breakthrough Antimicrobial Formulation
for Over-The-Counter Non-Wound Market to be Launched in U.S. Without
Pre-Approval by the FDA
June 11, 2008
Oculus
Innovative Sciences Announces Fiscal Fourth Quarter and Full Year
2008 Financial Results and Corporate Update
June 5, 2008
Oculus
Innovative Sciences Announces Fiscal Fourth Quarter and Full Year
2008 Financial Results and Corporate Update Release and Conference
Call
June 4, 2008
Oculus
Innovative Sciences Files for Patent Protection on Breakthrough Wound
Care Device to Accelerate Wound Healing
June 2, 2008
Oculus
Innovative Sciences Announces Market Assessment of Near-Term Commercialization
Opportunities in the United States for Dermacyn™ Wound Care
May 28, 2008
Oculus
Innovative Sciences Announces Publication of Microcyn® Technology
Post-Caesarean Section Wound Study in Indian Medical Gazette
May 15, 2008
Oculus
Innovative Sciences to Participate in Third Congress of the World
Union of Wound Healing Societies in Toronto
May 5, 2008
Oculus
Innovative Sciences Announces Initial Chinese Commercialization Plan
for Launch of Microcyn® Technology
April 23, 2008
Oculus
Innovative Sciences Appoints Michelle Carpenter, JD, RAC, as Vice
President of Regulatory Affairs and Quality
April 17, 2008
Oculus
Innovative Sciences' CEO and Founder Hoji Alimi Featured on NASDAQ
CEO Signature Series
April 15, 2008
Oculus
Innovative Sciences Announces Publication of Microcyn® Technology
Diabetic Wound Study in Journal of College of Physicians and Surgeons
Pakistan
March 28, 2008
Oculus
Innovative Sciences, Inc., Announces $13.9 Million Securities Offering
March 27, 2008
Oculus
Innovative Sciences Receives Chinese SFDA Regulatory Approval of
Microcyn® Technology
March 17, 2008
Oculus
Innovative Sciences Announces Positive Results From Three Abstracts
Evaluating the Use of Microcyn® Technology in Diabetic Foot Ulcers
March 14, 2008
Oculus
Innovative Sciences Announces Additional Phase II Data for Microcyn®
Technology in Mildly Infected Diabetic Foot Ulcers
March 12, 2008
Oculus
Innovative Sciences Announces Acceptance of Three Abstracts on the
use of Microcyn® Technology in Diabetic Foot Ulcers by DFCon
08
March 11, 2008
Oculus
Innovative Sciences to Announce Additional Phase II Data and Data
from Two Recent International Studies at DFCon 08
February 27, 2008
Oculus
Innovative Sciences Schedules Conference Call Today to Discuss Positive
Top-Line Phase II Data with Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
February 27, 2008
Oculus
Innovative Sciences Announces Positive Top-Line Phase II Data with
Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers
February 14, 2008
Oculus
Innovative Sciences to Present at the Roth Capital Partners 20th
Annual OC Growth Stock Conference
February 7, 2008
Oculus
Innovative Sciences Announces Fiscal Third Quarter 2008 Quarterly
Results and Clinical Update
February 5, 2008
Oculus
Schedules Fiscal Third Quarter 2008 Financial Results Release and
Conference Call
January 29, 2008
Oculus
Innovative Sciences Announces Agreement with Animal Health International
for North American Distribution of Microcyn®-Based Vetericyn™ Wound
Spray
January 24, 2008
Oculus
Innovative Sciences Awarded Damages by Federal Court in Intellectual
Property Rights Litigation
January 22, 2008
Top-Line
Data from Oculus Innovative Sciences' Phase II Trial to Be Presented
at DFCon 08 (Diabetic Foot Global Conference) on March 14, 2008
January 17, 2008
Oculus
Innovative Sciences, Inc. Appoints Gregg Alton to its Board of Directors
January 3, 2008
Oculus
Innovative Sciences Completes Patient Treatment and Follow-up in
Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
2007
December 18, 2007
Oculus
Innovative Sciences Announces Completion of Two Randomized Controlled
Clinical Trials of Microcyn® Technology in China
December 5, 2007
Oculus
Innovative Sciences Completes Enrollment of Phase II Trial of Microcyn® Technology
in Treatment of Mildly Infected Diabetic Foot Ulcers
November 19, 2007
Oculus
Innovative Sciences Wins Federal Court Ruling in Intellectual Property
Rights Litigation
November 12, 2007
Oculus
Innovative Sciences Announces Fiscal Second Quarter 2008 Quarterly
Results and Clinical Update
November 8, 2007
Oculus
Innovative Sciences Schedules Fiscal Second Quarter 2008 Financial
Results Release and Conference Call
November 1, 2007
Oculus
Innovative Sciences to Present at SMH Capital Markets Investor Growth
Conference
October 30, 2007
Oculus
Innovative Sciences to Present at Acumen BioFin 9th Annual Healthcare
Conference
October 3, 2007
Oculus
Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference
September 17, 2007
Oculus
Innovative Sciences Microcyn Technology Data to be Presented by Researchers
at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
September 17, 2007
Oculus
Innovative Sciences Provides Update of Phase II Study for Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
September 14, 2007
Oculus
Innovative Sciences to Conduct Conference Call Update on Phase II
Study of Microcyn® Technology in Mildly Infected Diabetic Foot
Ulcers
September 6, 2007
Oculus
Innovative Sciences to Present at First Albany Capital Regenerative
Technologies Conference
August 29, 2007
Oculus
Innovative Sciences to Present at Roth Capital Partners 2007 New
York Conference
August 9, 2007
Oculus
Innovative Sciences Announces Fiscal First Quarter 2008 Financial
Results
August 8, 2007
Oculus
Innovative Sciences Announces $10.1 Million Private Placement of
Common Stock
August 3, 2007
Oculus
Innovative Sciences Schedules Fiscal First Quarter 2008 Financial
Results Release and Conference Call
June 26, 2007
Oculus
Innovative Sciences Announces Results From Anti-Inflammatory Study
Using Microcyn® Technology
June 18, 2007
Oculus
Innovative Sciences Appoints Vice President of Regulatory Affairs
and Quality
June 13, 2007
Drug
Enhancement Company of America Licenses Oculus' Microcyn® Technology
for Use in First Responder ''Pen-Like'' Applicator
June 7, 2007
Oculus
Announces Fiscal Fourth Quarter and Full Year 2007 Financial Results
June 6, 2007
Oculus
Schedules Fiscal Fourth Quarter and Full Year 2007 Financial Results
Release and Conference Call
May 21, 2007
Oculus
Initiates Patient Enrollment in Phase II Study of Microcyn® Technology
for Treatment of Mild Diabetic Foot Infections
May 14, 2007
Oculus
Innovative Sciences Microcyn® Technology Presented in Poster
at European Wound Management Association Conference
May 9, 2007
Oculus
Innovative Sciences to Present at Rodman & Renshaw Global Healthcare
Conference
April 26, 2007
China
Bao Tai, Sinopharm and Lianhua Supermarkets to Distribute Oculus'
Microcyn®-Based Wound Care Solution in China
April 25, 2007
Oculus
Innovative Sciences, Inc. Appoints Jay E. Birnbaum to Its Board of
Directors
March 29, 2007
Oculus
Announces Initial Sites for Phase II Clinical Trial of Microcyn® Technology
in Treatment of Mild Diabetic Foot Infections
March 13, 2007
Oculus'
Dermacyn® Wound Care Subject of 33-Patient Study Published in International
Journal of Lower Extremity Wounds
February 22, 2007
Oculus
Innovative Sciences Announces Fiscal Third Quarter 2007 Results
January 24, 2007
Oculus Innovative Sciences,
Inc. Announces Initial Public Offering
2006
July 11, 2006
Pharmaceutical Veteran
Michael Wokasch Joins Oculus Innovative Sciences As Chief Operating
Officer
March 8, 2006
Dermacyn® Wound
Care OTC Receives FDA Clearance for Over-The-Counter Sales In The
United States.
February 23, 2006
Oculus Innovative
Sciences Introduces New 500 mL Packaging of Dermacyn® Wound
Care
2005
October 4, 2005
Results of Clinical
Study Evaluating Treatment of Diabetic Foot Ulcers Using Microcyn® Technology
Presented At Stuttgart2005.
June 17, 2005
Oculus Innovative
Sciences Announces Company's First U.S. Clinical Trial On Humans.
May 18, 2005
Oculus Innovative
Sciences Announces Second FDA 510k Clearance of Microcyn® Technology.
May 9, 2005
Oculus Innovative
Sciences Announces FDA 510k Clearance of Microcyn® Technology.
2004
November 24, 2004
Dermacyn® Wound
Care From Oculus Innovative Sciences Receives CE Mark Approval For
Treating Acute and Chronic Wounds In Europe.
(PDF: 82 KB)
November 19, 2004
European
Facility is Approved for Manufacturing of Revolutionary Microcyn® Technology.
(PDF: 88 KB)
November 1, 2004
Oculus
Receives Regulatory Approval To Market Dermacyn® Wound
Care in Canada.
May 14, 2004
Oculus
Files 510(K) with FDA for Approval of Microcyn as Wound Care Dressing.
(PDF: 92 KB)
May 14, 2004
Oculus
Files Application with U.S. EPA for Approval of Microcyn as a Hospital-Grade
Disinfectant.
(PDF: 90 KB)
May 1, 2004
Oculus
Closes Series "A" Round of Financing for $8 Million.
(PDF: 93 KB)
April 16, 2004
Mexican
Ministry of Health Approves Microcyn Technology for Use in Veterinarian
Market.
(PDF: 93 KB)
March 31, 2004
Oculus
Microcyn60 Disinfectant (OMD) Technology Receives CE Mark Approval
as Disinfectant for Non-Critical Medical Devices in Europe.
(PDF: 94 KB)
January 9, 2004
Oculus
Applies for CE Mark Approval for California Manufacturing Facility.
(Corrected Jan. 11, 2004)
(PDF: 92 KB)
January 9, 2004
Microcyn
Receives Approval as a Sterilant from Mexican Ministry of Health.
(PDF: 90 KB)
2003
December 19, 2003
Oculus
Completes Incorporation of Legal Entity in the Netherlands and Prepares
for Opening of European Manufacturing Facility for Microcyn Technology.
(PDF: 92 KB)
November 11, 2003
Oculus
Innovative Sciences Launches Microcyn in Mexico.
(PDF: 94 KB)
October 1, 2003
Oculus
Files for Pre-Investigational Meeting with FDA to Review Microcyn60
Antiseptic Technology.
(PDF: 90 KB)
September 18, 2003
MicroMed Consulting
Group Announces Strategic Partnership with Roberts Consulting & Engineering.
(PDF: 92 KB)
September 9, 2003
Oculus Innovative
Sciences Opens European Office as Company Seeks CE Mark Approval
of Microcyn60 Disinfectant and Antiseptic.
(PDF: 91 KB)
September 9, 2003
Jim Schutz
Joins Oculus Innovative Sciences as General Counsel and Corporate
Secretary.
(PDF: 90 KB)
September 2, 2003
Dr. Andres
Gutierrez of Mexican Ministry of Health Joins Oculus Advisory Board.
(PDF: 91 KB)
August 28, 2003
Mexico's Ministry
of Health to Initiate Limited Clinical Trials of Oculus's "L3" Oncology
Compound in Treatment of Cervical Cancer.
(PDF: 92 KB)
August 14, 2003
Oculus Innovative
Sciences Announces Appointment of Executive Vice President and Director
of Business Development.
(PDF: 93 KB)
July 31, 2003
Microcyn60
Disinfectant from Oculus Innovative Sciences Receives Mexican Ministry
of Health Approval.
(PDF: 92 KB) |
